Additionally, a low molecular weight MUC1 cleavage product, MUC1*, that remains membrane bound has recently been shown to be a determinant of trastuzumab resistance in HER2+ breast cancer [44] and functions as a growth factor receptor [45], [46]. This evidence concerns the gene ERBB2 and breast carcinoma.